Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK’s Relvar Ellipta succeeds in Salford lung study
Headline results from the 2,802-patient Salford Lung Study (SLS) in COPD showed that the inhaled therapy achieved a superior reduction in exacerbations versus usual care – which included
Headline results from the 2,802-patient Salford Lung Study (SLS) in COPD showed that the inhaled therapy achieved a superior reduction in exacerbations versus usual care – which included
This presents the possibility of completing the clinical development program with only one pivotal efficacy study in each of the two indications being focused on by Isofol (colorectal
Andrew Lees, MD FRCP, FMedSci, Professor of Neurology, (The National Hospital for Neurology and Neurosurgery, Queen Square and Emeritus Director, Reta Lila, Weston Institute of Neurological Studies, University
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for cabozantinib compared with sunitinib in patients with advanced intermediate-
Vtesse’s ongoing Phase 2b/3 prospective, randomized, double-blind, sham-controlled trial is a three-part, efficacy and safety trial of VTS-270, administered by the lumbar intrathecal (IT) route every two weeks.
Rituximab is a monoclonal antibody that is used to treat non-Hodgkin’s lymphoma, which includes follicular lymphoma and diffuse large B-cell lymphoma, chronic lymphocytic leukemia and autoimmune diseases such
The objective of SPARTAN is to evaluate the safety and efficacy of lasmiditan (50 mg, 100 mg and 200 mg) in comparison to placebo two hours after dosing
Patients will be at least 18 years of age with a maximum of 10% treatable body surface area (BSA) involvement of plaque psoriasis. Up to 15 patients will
Anavex Life Sciences president and CEO Christopher U. Missling said: "The Orphan Drug Designation marks the first U.S. movement for ANAVEX 2-73. Rett syndrome is a devastating disease
BioPharma Services CEO Renzo DiCarlo said: "We are very proud to work with the FDA in support of their Generic Drug programs. This award is a great example